SCHEDULE 13G: Intracoastal Capital and Affiliates Disclose 6.9% Stake in NAYA Biosciences

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 6.9% in NAYA Biosciences Inc. common stock, totaling 504,478 shares.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G, disclosing their beneficial ownership in NAYA Biosciences Inc.
• As of January 16, 2025, the Reporting Persons collectively beneficially own 504,478 shares of NAYA Biosciences Inc. common stock.
• This ownership represents approximately 6.9% of the company's common stock.
• The shares consist of 320,478 shares directly held by Intracoastal Capital LLC and 184,000 shares issuable upon the exercise of Intracoastal Warrant 1.
• The beneficial ownership calculation is based on 4,476,220 shares outstanding prior to the Securities Purchase Agreement (SPA) and an additional 2,611,600 shares issued at the closing of the SPA transaction, plus the 184,000 shares from Warrant 1.
• The filing notes that certain blocker provisions in Intracoastal Warrant 1 (9.99% limit) and Intracoastal Warrant 2 (4.99% limit) prevent the exercise of additional shares that would exceed these thresholds.
• Without these blocker provisions, the Reporting Persons would have beneficial ownership of 857,478 shares as of January 16, 2025.
• The acquisition of these securities was not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership, indicating an investment by a group of investors in NAYA Biosciences Inc. The investment itself can be seen as a positive signal, but the document does not contain performance data or forward-looking statements to significantly sway sentiment.

Positives

• A significant investment by institutional and individual investors (Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher) indicates confidence in NAYA Biosciences Inc.
• The investment was made through a Securities Purchase Agreement, suggesting a structured transaction and potentially providing capital to the company.

Negatives

• The presence of blocker provisions in warrants suggests that the investors are limited in their ability to increase their stake beyond certain thresholds (9.99% and 4.99%), which could limit their influence or further investment without triggering additional disclosure requirements or control considerations.

Risks

• The document itself is a disclosure of ownership and does not detail specific operational or financial risks of NAYA Biosciences Inc. The primary risk mentioned is related to the blocker provisions limiting the exercise of warrants, which could affect the full realization of potential ownership by the reporting persons.

Future Outlook

NA

Industry Context

This filing indicates a significant investment in a biotechnology company (implied by "NAYA Biosciences Inc." and common stock). Such investments are common in the biotech sector for funding research, development, or general operations.

Related Party Transactions

• The Securities Purchase Agreement (SPA) between NAYA Biosciences Inc. and Intracoastal Capital LLC (and its affiliates) could be considered a related party transaction if the reporting persons have significant influence or control over the issuer, though the 13G itself doesn't explicitly label it as such. The filing states the acquisition was not for the purpose of changing or influencing control.

Stakeholder Impact

• Shareholders: The issuance of new shares (2,611,600 shares in aggregate at closing) and warrants could lead to dilution for existing shareholders. The disclosure of a significant new shareholder group (6.9%) could influence market perception.
• Company (NAYA Biosciences Inc.): The Securities Purchase Agreement likely provided capital to the company, which can be used for operations, research, or other strategic initiatives.

Key Dates

Keywords

NAYA Biosciences Inc., Common Stock, Schedule 13G, Beneficial Ownership, Intracoastal Capital LLC, Mitchell P. Kopin, Daniel B. Asher, SEC Filing, Investment, Warrants, Securities Purchase Agreement